Approved regulatory verdict
Evidence outlook
Approved: unresectable or metastatic melanoma with BRAF V600E mutation as detected by an... (FDA)
This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational. Regulatory approval supersedes design-level evidence grading for the approved use.
track record: Weak signal
Source for the program status
How the evidence outlook works ↗
Featured trials The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Non-Small Cell Lung Cancer · investigational · Featured evidence · 2 Malignant Melanoma · not a covered market · Outside covered markets · 1 Melanoma · not a covered market · Outside covered markets · 1 investigational Featured evidence · 2
Competitive landscape 61 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 60 same-indication; 58 further along in development.
Unlock with Research ↗ Drug Stage Modality Mechanism Evidence signal Reported efficacygraded featured trials Vemurafenib: this drug Phase 3 Small molecule BRAF (V600 mutant) ABM-1310 Phase 1 Small molecule BRAF (V600 mutant) Afatinib (Gilotrif)Approved Small molecule EGFR/HER1, HER2, HER4 Alectinib (Alecensa)Approved Small molecule ALK Alymsys (bevacizumab-Maly) Approved Monoclonal antibody VEGF-A Amivantamab Approved Multispecific antibody EGFR x c-MET Atezolizumab Approved Monoclonal antibody PD-L1 BAT1706 (Avzivi)Approved Monoclonal antibody VEGF-A BAY2927088 (Hyrnuo)Approved Small molecule HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR Bevacizumab Approved Monoclonal antibody VEGF-A , Vascular Endothelial Growth Factor Inhibitor Bevacizumab-Awwb (MVASI)Approved Monoclonal antibody VEGF-A Binimetinib Approved Small molecule MEK1/2 Brigatinib Approved Small molecule ALK Capmatinib Approved Small molecule MET Cemiplimab Approved Monoclonal antibody PD-1 Ceritinib Approved Small molecule ALK
…and 46 more. Research shows the complete landscape.
Research Unlock the full comparison Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Unlock with Research ↗ Upcoming events (18 total) Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (5) November 2026 (3) Phase 2 Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary Carcinoma Recruiting
Est. primary completion 2026-11-22 ·
NCT06440850 ·
CT.gov ↗ What to watch Phase 2 Advanced Cancer, Solid Tumor, Haematological Malignancy Recruiting
Est. primary completion 2026-11-25 ·
NCT05159245 ·
CT.gov ↗ What to watch Phase 2 Non-Small Cell Lung Cancer Recruiting
Est. primary completion 2026-11-30 ·
NCT04302025 ·
CT.gov ↗ What to watch December 2026 (2) Phase 3 Colorectal Cancer Metastatic Recruiting
Est. primary completion 2026-12-24 ·
NCT06008119 ·
CT.gov ↗ What to watch Phase 2 Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors Recruiting
Est. primary completion 2026-12-31 ·
NCT03297606 ·
CT.gov ↗ What to watch 2027 (8) January 2027 (1) Phase 2 Hairy Cell Leukemia, Leukemia, Leukemia, Hairy Cell Active not recruiting
Est. primary completion 2027-01 ·
NCT03410875 ·
CT.gov ↗ What to watch June 2027 (2) Phase 2 Histiocytosis Recruiting
Est. primary completion 2027-06-30 ·
NCT04943198 ·
CT.gov ↗ What to watch Phase 2/3 Non-Small Cell Lung Cancer Active not recruiting
Est. primary completion 2027-06-30 ·
NCT03178552 ·
CT.gov ↗ What to watch July 2027 (1) Phase 2 Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8 … Active not recruiting
Est. primary completion 2027-07-31 ·
NCT03181100 ·
CT.gov ↗ What to watch September 2027 (2) Phase 2 Cancer, Tumors, Neoplasm, Neoplasia Recruiting
Est. primary completion 2027-09 ·
NCT02925234 ·
CT.gov ↗ What to watch Phase 2 Hairy Cell Leukemia Recruiting
Est. primary completion 2027-09-09 ·
NCT06561360 ·
CT.gov ↗ What to watch December 2027 (2) Phase 2 Rare Tumour Not yet recruiting
Est. primary completion 2027-12-31 ·
NCT06692491 ·
CT.gov ↗ What to watch Phase 2 Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors Recruiting
Est. primary completion 2027-12-31 ·
NCT02693535 ·
CT.gov ↗ What to watch 2028 (2) July 2028 (1) Phase 3 Cancer Active not recruiting
Est. primary completion 2028-07-05 ·
NCT03768063 ·
CT.gov ↗ What to watch September 2028 (1) Phase 2 Thyroid Cancer Active not recruiting
Est. primary completion 2028-09-30 ·
NCT01709292 ·
CT.gov ↗ What to watch 2029 (3) April 2029 (1) Phase 2 Cancer, Tumors, Neoplasms, Neoplasia Recruiting
Est. primary completion 2029-04-30 ·
NCT04341181 ·
CT.gov ↗ What to watch October 2029 (2) Phase 2/3 Non-Small Cell Lung Cancer Recruiting
Est. primary completion 2029-10 ·
NCT05768178 ·
CT.gov ↗ What to watch Phase 2/3 Haematological Malignancy, Solid Tumour Recruiting
Est. primary completion 2029-10 ·
NCT05722886 ·
CT.gov ↗ What to watch See the full readout calendar ↗
All registered studies Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.
All indications (146) Non-Small Cell Lung Cancer (6) Other / comorbidity (140)
Phase 3 (8) Phase 2/3 (3) Phase 2 (70) Phase 1/2 (9) Phase 1 (50) Phase 4 (3) Early phase / not applicable (3) Used as active comparator (2) Appears in other studies (4)